Completed PHASE3 INTERVENTIONAL 2-arm NCT00820651

Efficacy and Safety of Diamel in Patients With Nonalcoholic Steatohepatitis

Efficacy and Safety of Diamel, a Nutritional Supplement, in Patients With Nonalcoholic Steatohepatitis. A Randomized and Double Blind Controlled Study

Sponsor: Catalysis SL

Conditions Insulin Resistance Nonalcoholic Steatohepatitis

Interventions Diamel Placebo and lifestyle counseling

Updated 5 times since 2017 Last updated: Apr 25, 2012 Started: Nov 30, 2009 Primary completion: Apr 30, 2012 Completion: Apr 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Insulin Resistance and Nonalcoholic Steatohepatitis, this trial is completed. The trial is conducted by Catalysis SL and has accumulated 5 data snapshots since 2009. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Catalysis SL

Data source: Catalysis SL

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Vedado, Cuba